Document is current
Any future updates will be listed below
-
Authors
Spargo, Thomas P. https://orcid.org/0000-0003-4297-6418
Opie-Martin, Sarah https://orcid.org/0000-0003-0951-8589
Bowles, Harry https://orcid.org/0000-0002-4072-5255
Lewis, Cathryn M. https://orcid.org/0000-0002-8249-8476
Iacoangeli, Alfredo https://orcid.org/0000-0002-5280-5017
Al-Chalabi, Ammar https://orcid.org/0000-0002-4924-7712
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/L501529/1, MR/R024804/1)
Economic and Social Research Council (ES/L008238/1)
Maudsley Charity (980)
Guy's and St Thomas' Charity (TR130505)
Horizon 2020 (H2020-PHC-2014-two-stage, 633413)
MND Scotland
South London and Maudsley NHS Foundation Trust
Motor Neurone Disease Association
National Institute for Health and Care Research
Spastic Paraplegia Foundation
Rosetrees Trust
Darby Rimmer MND Foundation
Alzheimer’s Research UK
- License Information
-
More Information
Article History
Received: 13 June 2022
Accepted: 18 November 2022
First Online: 15 December 2022
Declarations
:
: Not applicable.
: Not applicable.
: CML sits on the SAB for Myriad Neuroscience. AAC reports consultancies or advisory boards for Amylyx, Apellis, Biogen Idec, Brainstorm, Cytokinetics, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma, Quralis, and Wave Pharmaceuticals.The remaining authors declare that they have no competing interests.
